Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations.
• Pathogenesis involves dysregulated innate and adaptive immunity, leading to autoantibody production and immune complex-mediated organ damage.
• Current treatments focus on anti-inflammatory and immunosuppressive therapies, with recent advancements in targeted biologicals.

Purpose of the Study:

• To evaluate the therapeutic potential of targeting interleukin-17 (IL-17) and T helper 17 (Th17) cells in Systemic Lupus Erythematosus (SLE).
• To review the existing evidence for Th17-targeted therapies in SLE, particularly in lupus nephritis.
• To discuss the implications of SLE heterogeneity for single-molecule targeted therapies.

Main Methods:

• Literature review of studies investigating IL-17 and Th17 pathways in SLE.
• Analysis of current therapeutic strategies for SLE and related autoimmune conditions.
• Discussion of the role of IL-17 in SLE pathogenesis and potential treatment responses.

Main Results:

• Interleukin-17 (IL-17) is a key pro-inflammatory cytokine implicated in SLE pathogenesis.
• Th17-targeted therapies, including IL-17 inhibitors, are established for other autoimmune diseases like psoriatic arthritis.
• Evidence for Th17-targeted therapy efficacy in SLE is limited, with the most promise observed in lupus nephritis.

Conclusions:

• Targeting IL-17 and Th17 cells presents a potential therapeutic avenue for specific SLE manifestations, especially lupus nephritis.
• Given SLE's complexity and heterogeneity, inhibiting a single molecule like IL-17 is unlikely to be effective for all patients or disease facets.
• Future research should focus on identifying SLE patient subgroups who would benefit most from Th17-targeted therapies.